Celgene Corporation
Jun 16, 2011
Add to Briefcase

Phase II Study Evaluates Clinical Benefit of Combining REVLIMID® with rituximab to Enhance Anti-Cancer Activity in Mantle Cell Lymphoma

Study Reports 57.8% Overall Response Rate, 32.6% Complete Remission Rate and Median Overall Survival of 25 Months
Study Further Validates Therapeutic Potential of Antibody Dependent Cellular Mediated Cytotoxicity (ADCC)

BOUDRY, Switzerland, Jun 16, 2011 (BUSINESS WIRE) --

Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase I/II study evaluating the combination of REVLIMID® (lenalidomide) plus rituximab (R2) in relapsed/refractory mantle cell lymphoma (MCL), conducted by investigators at the MD Anderson Cancer Center in Houston, TX, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

Patients with MCL who had received one to four prior therapies received REVLIMID daily on days one to 21 of each 28-day cycle, and rituximab weekly for four doses during cycle one. The maximum tolerated dose in the phase I portion was 20 mg of REVLIMID daily, and 375 mg/m2 of rituximab in accordance with the study schedule.

Forty-six patients were enrolled in the Phase II portion of the study. The overall response rate was 57% with a complete response rate of 33% and a median duration of response of 18.9 (range 17-NR) months. After a median follow-up of 23.1 months, the median progression free survival and median overall survival were 13 months (95% CI 8.3-20.8) and 25.1 months (95% CI 19.8-NR), respectively. The combination regimen induced complete responses in two patients with bulky MCL and induced responses in patients who were refractory to or who did not tolerate prior treatment with bortezomib. The investigators have hypothesized that REVLIMID may enhance the effects of rituximab on ADCC (antibody-dependent cellular mediated cytotoxicity), or the ability of the body to direct immune defense cells to attack lymphoma cells.

The combination REVLIMID plus rituximab was well tolerated. Primary grade 3-4 toxicities included neutropenia (17%), lymphopenia (7.2%), and thrombocytopenia (4.5%).

These data are from investigational studies. REVLIMID does not have marketing approval for the treatment of mantle cell lymphoma.


REVLIMID® is an IMiDs® compound. REVLIMID and other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of-matter and use patents.

REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Marketing Authorization Applications are currently being evaluated in a number of other countries.

Important Safety Information

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.

REVLIMID is indicated for patients with transfusion-dependent anaemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Important Safety Information


Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or death to a developing baby. In women of childbearing potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Women of childbearing potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid fetal exposure to lenalidomide, REVLIMID is only available under a restricted distribution program called "RevAssist®."

Information about the RevAssist program is available at www.REVLIMID.com or by calling the manufacturer's toll-free number 1-888-423-5436.


REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. (see DOSAGE and ADMINISTRATION)


REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with MM who were treated with REVLIMID and dexamethasone therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.


Pregnancy Category X:

Allergic Reactions:


Fetal Risk:

Reproductive Risk and Special Prescribing Requirements (RevAssist Program):

Haematologic Toxicity--Multiple Myeloma:

Deep Vein Thrombosis:

Allergic Reactions:

Tumour Lysis Syndrome:

Tumour Flare Reaction:



Nursing Mothers:

Geriatric Use:

Renal Impairment:


Multiple Myeloma

Myelodysplastic Syndromes


Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.

About Mantle-Cell Lymphoma

MCL is one of several subtypes of NHL and results from a malignant transformation of a B lymphocyte in the mantle zone - the outer edge of the lymph node follicles. The uncontrolled growth of the transformed lymphocytes, or lymphoma cells, cause tumors to form in the lymph nodes, which then become enlarged. Lymphoma cells can also spread to other tissues, such as the marrow, liver and gastrointestinal tract.

MCL is distinguished from other subtypes of B-cell lymphoma by abnormal expression of cyclin D1, a protein that stimulates cell growth. Approximately 85 percent of MCL cases are caused by genetic changes involving the cyclin D1 gene on chromosome 11 and chromosome 14.

About ADCC (antibody-dependent cell-mediated cytotoxicity)

ADCC is an immune defense mechanism that directs natural killer cells, T cells, macrophages and other immune cells to cause cancer cell death. Antibodies such as rituximab target receptors on lymphoma cells to induce ADCC. In addition to being an immunomodulatory agent with direct and indirect cancer activity, REVLIMID may also enhance the ADCC process against cancer cells.

About Celgene Risk-Management

Celgene continues to be a pioneer in creating environments in which patients who can benefit from our disease-altering therapies are able to do so, and do so safely. We are fully committed to drug lifecycle safety, from clinical development to post-marketing surveillance. As a result, patients worldwide continue to benefit from our risk-management programs such as, S.T.E.P.S. ®, RevAssist®, RevMate® and PRMP, which form the global foundation of our commitment to patient safety.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

SOURCE: Celgene International Sàrl

Celgene International Sàrl
Kevin Loth, +41 32 729 86 21
Director of External Relations